NOC

Northrop Grumman reported record $110 billion backlog with 1.5x book-to-bill ratio, driven by strong defense spending. The company projects sales growth acceleration from 5% to 7% in 2027 across all four operating segments, supported by increased production on key programs like the B-21 Raider bomber. Management is also exploring commercialization of specialized microelectronics and quantum technology to expand beyond traditional defense contracts.

Northrop Grumman reported Q3 2026 earnings of $7.89 per share, beating consensus estimates of $7.22 and revenues of $11.12 billion, slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 22.9 percentage points year-to-date, declining 10.5% while the market gained 12.4%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

The U.S. Air Force rejected Northrop Grumman's design for its Collaborative Combat Aircraft (CCA) program, awarding contracts instead to privately-held General Atomics and Anduril Industries. Undeterred, Northrop Grumman is developing the YFQ-48A Talon Blue drone independently using internal R&D funding, with plans to potentially compete in the CCA program's second increment. However, the analyst cautions that investing in Northrop based on CCA hopes is risky, citing its modest valuation metrics and growth rate.